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Abstract
Background: Rheumatoid arthritis (RA) is associated with a high prevalence of atherosclerosis. Recently increased
levels of microparticles (MPs) have been reported in patients with RA. MPs could represent a link between autoimmunity
and endothelial dysfunction by expressing tumor necrosis factor alpha (TNFα), a key cytokine involved in the pathogenesis
of RA, altering endothelial apoptosis and autophagy. The aim of this study was to investigate TNFα expression on MPs and
its relationship with endothelial cell fate.
Methods: MPs were purified from peripheral blood from 20 healthy controls (HC) and from 20 patients with
RA, before (time (T)0) and after (T4) 4-month treatment with etanercept (ETA). Surface expression of TNFα was
performed by flow cytometry analysis. EA.hy926 cells, an immortalized endothelial cell line, were treated with
RA-MPs purified at T0 and at T4 and also, with RA-MPs in vitro treated with ETA. Apoptosis and autophagy
were then evaluated.
Results: RA-MPs purified at T0 expressed TNFα on their surface and this expression significantly decreased at
T4. Moreover, at T0 RA-MPs, significantly increased both apoptosis and autophagy levels on endothelial cells,
in a dose-dependent manner. RA-MPs did not significantly change these parameters after 4 months of in vivo
treatment with ETA.
Conclusions: Our data demonstrate that MPs isolated from patients with RA exert a pathological effect on
endothelial cells by TNFα expressed on their surface. In vivo and in vitro treatment with ETA modulates this
effect, suggesting anti-TNF therapy protects against endothelial damage in patients with RA.
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Background
Microparticles (MPs) are small membrane vesicles (0.1–
1.0 μm) released by many cell types under physiological
and pathological conditions. In the past these particles
were considered as inert cell debris, but recently many
studies have demonstrated they could be involved in
intercellular communication. Generation and scattering
of MPs occurs during different biological processes, in-
cluding apoptosis and cellular activation [1–3]. Due to
their formation, MPs have an array of surface markers
derived from their parental cell that can be used to as-
sess their origin. Thus, MPs can transfer biological mes-
sages from parental to target cells by direct interaction
with the ligands expressed on the surface of target cells
and activate cascade signaling; or they can transfer pro-
teins, messenger RNA (mRNA), micro RNA (miRNA),
and bioactive lipids by fusion or internalization with tar-
get cells [4].Thus, MPs are able to modulate various
biological phenomena such as cell proliferation, angio-
genesis, immune response, and coagulation [5, 6].
Increased levels of MPs have been reported in various
pathological conditions including infections, malignancies,
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and autoimmune diseases, such as rheumatoid arthritis
(RA) [7]. RA is an autoimmune systemic inflammatory
disease characterized by chronic synovial inflammation,
resulting in cartilage and bone damage with accelerated
atherosclerosis and increased mortality [8]. Tumor necro-
sis factor alpha (TNFα) is the main cytokine involved in
the pathogenesis of RA and many studies agree on the
pro-atherogenic effect of TNFα in patients with RA.
TNF-inhibitors are effective treatments for joint inflam-
mation in RA; however, very little is known about their ef-
fect on atherosclerosis and endothelial dysfunction, which
occur in this disease. Previous studies have shown that
TNF-inhibitors can improve endothelial function and de-
crease cardiovascular events in responder patients, highlight-
ing the pro-atherogenic effect of TNFα in RA [9, 10].
According to the literature, MPs could also have a role
in endothelial dysfunction, contributing to atheroscler-
osis in patients with RA [11]. Moreover, an imbalance
between apoptosis and autophagy mechanisms seems to
be involved in endothelial dysfunction. Apoptosis is pro-
grammed cell death and many studies suggest the in-
volvement of endothelial apoptosis in the atherosclerosis
process [12]. Autophagy is a reparative process by which
cytoplasmic components are sequestered in double-
membrane vesicles and degraded on fusion with lyso-
somal compartments. It has been shown that basal
autophagy is essential to proper vascular function [13].
Taking into account these considerations, the aim of
this study was to analyze MP subsets in patients with
RA and their contribution to endothelial dysfunction,
with special focus on apoptosis and autophagy pathways,
and to investigate if biological therapy could modulate
these effects.
Materials and methods
Patients and controls
We enrolled 20 patients with RA fulfilling the 2010
American College of Rheumatology RA criteria [14], re-
cruited from the Rheumatology Unit of Sapienza Univer-
sity of Rome at time zero (T0) and after 4 months (T4)
of therapy with the TNF-inhibitor etanercept (ETA). The
main clinical and laboratory variables assessed were the
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), rheumatoid factor (RF) and anti-cyclic citrulli-
nated peptide (anti-CCP) titer, tender and swollen joint
count, patient’s assessment of pain, patient’s assessment
of disease activity, physician’s global assessment of dis-
ease activity, and the health assessment questionnaire
(HAQ). The European League Against Rheumatism
(EULAR) response to therapy was also recorded before
and after treatment. All patients had a history of failed
treatment with at least one disease-modifying antirheu-
matic drug (DMARD). Patients were allowed to continue
DMARDs, steroids, and non-steroidal anti-inflammatory
drugs at a stable dose for at least 4 weeks before and
during ETA treatment. Patients received ETA at a dose
of 50 mg given by subcutaneous injection (sc) weekly.
Methotrexate (MTX) was given at a dose of 10–20 mg
weekly. In addition to MTX, hydroxychloroquine (200–
400 mg daily) and steroids (maximum daily dose 10 mg
of oral prednisone or equivalent) were also permitted.
Simultaneously, 20 healthy controls (HC) within a
similar age range and gender as the patients were re-
cruited. Also 10 patients with RA who had only been
treated with traditional DMARDs were enrolled.
The protocol of study was approved by the Ethics
Committee of Sapienza University of Rome (Protocol
number 109/18), and informed written consent was ob-
tained from all patients prior to enrollment.
Isolation of MPs
A fasting blood sample was obtained from patients with
RA, at T0 and T4, and from HC by venipuncture in
5-ml tubes containing citrate, which were centrifuged
two times at 2500 g for 15 min at room temperature, to
obtain platelet-poor plasma (PPP), rich in MPs. The
resulting plasma was divided into five aliquots and
stored at − 80 °C until analysis [15, 16].
Energy-filtered transmission electron microscopy (EF-TEM)
For electron microscopy analysis MPs were centrifuged
at 14000 rpm for 1 h at 4 °C and pellets were fixed. The
samples were observed using a Zeiss EM902 transmis-
sion electron microscope, operating at 80 kV and
equipped with an “in column” electron energy filter. The
filter was set to collect only elastic electrons (ΔE 1/4 0),
with the result of enhancing image contrast and reso-
lution, thanks to the elimination of inelastic electrons in
the image formation (reduction of the chromatic aberra-
tion). The sample was stained with 2% (w/v) phospho-
tungstic acid (PTA) in buffered aqueous solution at
pH 7.3 (NaOH), previously filtered by polycarbonate
0.2-μm filters to eliminate impurities. Images were ac-
quired with a digital charge-coupled device camera,
model PROSCAN HSC2 (1 K × 1 K pixels), thermostated
by a Peltier unit. The analysis was performed using a
digital analyzer SIS 3.0. The overall resolution is in the
range of 2 nm [16].
Assessment of MP subsets and surface expression of
TNFα by flow cytometry
MPs were analyzed using a FACS Calibur cytometer
(Becton Dikinson, BD). Forward scatter (FSC) and side
scatter (SSC) were adjusted to logarithmic gain. MP gat-
ing was accomplished using 1-μm beads (SIGMA) for
setting upper limits in both FSC and SSC signals, and a
lower limit was placed to exclude buffer noise.
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Antibodies anti-CD41a–(Percp), anti-CD45–(APC)
anti-CD31–(PE) were added to MP samples to identify
specific MP subsets: platelet MPs (PMP (CD41a+
CD31+)), leukocyte MPs (LMP (CD45+)) and endothelial
MPs (EMP (CD41a− CD31+)) [17]. To evaluate the sur-
face expression of TNFα, MPs were incubated with anti-
bodies anti-TNFα–(fluorescein isothiocyanate (FITC)).
MPs were also labeled using FITC-conjugated Annexin-
V (AV). Fluorescent-conjugated isotype mAbs were used
as controls. Incubation was performed at room
temperature for 30 min in AV buffer and then MP sus-
pensions were transferred into count tubes that were im-
mediately processed by flow cytometry. MP number was
calculated as described [18, 19]. All antibodies were pur-
chased from BD Biosciences, San Josè, CA, USA.
RA-MP incubation with ETA
In vitro treatment of MPs was performed with ETA.
Briefly, 2*106 MPs/ml RA-MPs purified at T0 were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS), and treated
with ETA at different concentrations (1, 3, 5, and 10 μg/
ml) for 30 min, 2 h and 4 h. Surface expression of TNFα
was evaluated at the end of each time period.
In vitro culture of EA.hy926 cells
The in vitro effects of plasma-isolated MPs on the endo-
thelium were evaluated using human umbilical vein cell
line EA.hy926. Cells were cultured in DMEM containing
10% FBS, 50 IU/ml penicillin, 50 μg/ml streptomycin and
2mM l-glutamine at 37 °C under an atmosphere of 5%
CO2. To this end, MP suspensions purified from pa-
tients with RA at T0 and T4 and from HC were pre-
pared. Briefly, MPs were centrifuged at 14000 rpm for 1
h at room temperature and resuspended in DMEM 10%
FBS to obtain the desired concentration. Cells were cul-
tured with MP suspensions at different concentrations
(0.5, 2 and 8*106 MPs/ml) for 6 h, 16 h, 24 h, 48 h, and
72 h. Cells were also treated with RA-MPs pre-incubated
with ETA. Where indicated, cells were treated in the
presence of lysosomal inhibitors E64d and pepstatin A
(PepA) (both at 10 μg/ml; Sigma-Aldrich) for 2 h before
the end of the culture. For inhibition of autophagy, cells
were treated with 10mM 3-methyladenine (3MA),
which pharmacologically blocks this catabolic process
(Sigma-Aldrich). Apoptosis and autophagy were evalu-
ated at the end of experiments.
Evaluation of EA.hy926 cell apoptosis
After in vitro treatment with MPs, EA.hy926 cell apop-
tosis was analyzed by flow cytometry using a
FITC-conjugated Annexin V and propidium iodide
apoptosis detection kit [20] according to the manufac-
turer’s instructions (MBL).
Analysis of autophagy and TNF pathway by western blot
For analysis of autophagy EA.hy926 lysates (30 μg) were
loaded on SDS-PAGE and expression levels of the autopha-
gic markers LC3-II and P62 were analyzed by western blot
[21]. Rabbit anti-human p65 antibody was used for
NF-kB-p65 protein detection,. All antibodies were pur-
chased from Cell Signaling Technology, Beverly, MA, USA.
Statistical analysis
Normal distribution of variables was assessed using the
Kolmogorov-Smirnov test. Statistical analysis was performed
using the program GraphPad Prism Version 6 (GraphPad
Software, San Diego, CA, USA). The Mann–Whitney un-
paired test or Student’s t test was used to compare quantita-
tive variables in different groups. Statistical correlation was
examined using Spearman’s rank correlation coefficient.
Values of p < 0.05 were considered statistically significant.
Results
Patients and controls
The demographic, serological and clinical characteristics
of patients with RA and of HC are summarized in Table 1.
Electron microscopy
Transmission electron microscopy of PPP confirms the
purity of the samples used to conduct all our in vitro ex-
periments. The images show vesicles that are heteroge-
neous in terms of shape and density, with the majority
in the range of between 0.2 μm and 1 μm. Those sizes
represent the typical size of MPs that differ from exo-
somes and apoptotic bodies in size, composition and
mechanism of formation (Fig. 1).
Evaluation of MP subsets and surface expression of TNFα
The number of MPs in serum from patients with RA and
HC was quantified by flow cytometry analysis. The strat-
egy used to identify MP morphology, MP subsets and
TNFα expression is shown in Fig. 2a, b, and c.
Our study showed that at baseline the total number of
MPs was significantly increased in patients with RA com-
pared to HC (p < 0.0001) (Fig. 3a). Only the EMP subset
was significantly increased in patients with RA compared
to HC (p = 0.0049) (Fig. 3a). Interestingly, after 4 months
of in vivo treatment with ETA, the total number of MPs
and of the EMPs were both significantly decreased com-
pared to baseline (p < 0.0001 and p = 0.03, respectively)
(Fig. 3b). Moreover, after in vivo treatment with ETA, the
percentage of EMPs that were AV-positive decreased,
demonstrating downregulation of apoptosis of endothelial
cells in vivo (p = 0.03) (Fig. 3c). There were no differences
between seropositive and seronegative patients with RA
with regard to the levels of MPs (data not shown). As
shown in Fig. 3d the percentage of TNFα expressed on
the surface of MPs (sTNFα) was significantly increased in
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patients with RA compared to HC (p = 0.0009). After 4
months of in vivo treatment with ETA the percentage of
sTNFα was significantly decreased with respect to baseline
(p = 0.0002) (Fig. 3e). Instead, there was no significant
change in the percentage of sTNFα-MPs after therapy in
patients treated only with traditional DMARDs (data not
shown).This result corroborated our hypothesis on the
capacity of ETA to bind TNFα carried on the surface of
the MPs, as explained in the next paragraph. Moreover, as
shown in Additional file 1, in relation to the expression of
sTNF on MP subsets, we observed that EMPs expressed a
greater percentage of TNFα than PMPs. LMPs expressed
a high percentage of TNFα but this was not significantly
different to the percentage in the other subsets.
Finally, to compare the percentage of TNFα expressed
on the surface of the MPs and the serum TNFα, we also
performed ELISA of serum TNF on the same patients in
whom we evaluated the surface expression of TNFα on
MPs, as shown in Additional file 1.
Surface expression of TNFα on MPs after incubation with
ETA
We demonstrated for the first time the expression of TNF
on the surface of human MPs. On the basis of this result
we decided to incubate MPs with ETA at different con-
centrations in order to demonstrate that the drug was able
to bind and inhibit surface MP-TNFα expression. ETA, a
fully soluble, human dimeric fusion protein, functions as a
TNF inhibitor by competitively binding to TNF and pre-
venting its activation of the inflammatory cascade. ETA is
a soluble form of the p75 receptor that inhibits TNFα, by
blocking its interaction with cell-surface TNF receptors
and is different from adalimumab and infliximab, which
are monoclonal antibodies to TNF. Moreover, its peculiar-
ity with respect to the other TNFα inhibitors, is that be-
sides recognizing soluble TNFα, it also recognizes the
membrane-related portion.
For this reason, we hypothesized that ETA, in addition
to the soluble portion, recognizes and binds the portion
transported on the membrane of the MPs, preventing
the link with its receptor and then the inflammatory cas-
cade. Results obtained confirmed our hypothesis, in fact,
in vitro experiments showed that the percentage of
sTNFα expressed on RA-MPs significantly decreased, in
a dose-dependent manner, after incubation with ETA at
each timepoint of the experiment. In particular, the
major effect was at 10 μg/ml of ETA at (Fig. 4).
Table 1 Clinical, demographic, serological, and therapeutic
characteristics of patients with RA and HC
Patients with
RA (n = 20)
HC (n = 20)
Demographic parameters
Female/male 19/1 20/0
Age, years (median (IQR)) 58.5 (50–67) 58 (50–65)
Disease duration, years (mean ± SD), 5.3 ± 5.6
Disease activity
DAS28 (mean ± SD) 4.1 ± 1.7
TJ, n (mean ± SD) 6.16 ± 5.9
SJ, n (mean ± SD) 2.79 ± 2.7
CDAI (mean ± SD) 18.8 ± 10.7
HAQ (mean ± SD) 1.15 ± 0.8
Laboratory parameters N (%)
RF+ 15 (75)
ACPA+ 15(75)
ESR, mm/h (mean ± SD) 16.5 ± 10.3
CRP, mg/dl (mean ± SD) 0.7 ± 0.73
Therapy
Concurrent csDMARDs (n (%)) 20 (100)
ETA (n (%)) 20 (100)
RA rheumatoid arthritis, HC healthy controls, SD standard deviation, DAS28
Disease Activity Score in 28 joints, TJ tender joints, SJ swollen joints, CDAI
Clinical Disease Activity Index, HAQ Health Assessment Questionnaire, RF
rheumatoid factor, ACPA anti-citrullinated peptide antibodies, ESR erythrocyte
sedimentation rate, CRP C-reactive protein, csDMARDs conventional synthetic
disease-modifying antirheumatic drugs
Fig. 1 Transmission electron microscopy (TEM) of microparticles
(MPs). Micrographs show the negative staining of a typical sample
observed by the TEM. a White particles of different sizes ranging
from a few nanometers to 1 mm were present. As expected, all
particles appeared as white structures in the dark background, due
to phosphotungstic acid (PTA) negative staining. They were round-
shaped and sometimes superimposed. This observation suggests
that the smallest nanoparticles and MPs coexist in our sample,
because it is well-known that MP size ranges from 100 to 1000 nm.
b Two MPs of about 500 nm in diameter are shown, together with
their measured diameters. (Images from Miranda F. PhD Thesis)
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The percentage of sTNFα correlates with clinical
parameters of patients with RA
The purpose of our study was to test for correlation be-
tween MPs and endothelial damage. However, observing a
decrease in the surface expression of MP-TNFα and a
concomitant improvement in the parameters of disease
activity in patients after therapy with ETA, we decided to
test correlation between them. When we compared the
sTNFα of RA-MPs and clinical parameters, such as the
Disease Activity Score in 28 joints (DAS28), tender joints
(TJ), swollen joints (SW), CDAI and HAQ, identified sig-
nificant correlation between these parameters as shown in
Fig. 5. These results lead us to suppose there is a link be-
tween sTNFα on MPs and the status of patients’ disease.
Fig. 2 Gating strategy for flow cytometric analysis. a All microparticles (MPs) were gated as described in “Materials and methods”. b Flow cytometry
analysis of specific binding of antibodies to MPs derived from platelets, leukocytes and endothelial cells and annexin-V (AV). c MPs were also labeled
for the surface expression of TNFα. SSC, side scatter; FSC, forward scatter; FITC, fluorescein isothiocyanate; PMP, platelet MPs; LMP, leukocyte MPs; EMP,
endothelial MPs; APC, allophycocyanin; PE, phycoerythrin; PerCP, peridin chlorophyll protein; T0, time zero (baseline); T4, 4 months after treatment
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sTNFα of RA-MPs mediates in vitro induction of apoptosis
and autophagy in EA.hy926 cells
TNFα is the main cytokine involved in RA pathogenesis
and has a pathogenic effect, with a direct effect on endo-
thelial cells. Earlier studies have shown that TNFα inhibi-
tors are able to improve endothelial function and decrease
cardiovascular events in those patients who respond clin-
ically [9, 10]. After demonstrating the expression of TNFα
on the surface of MPs we decided to investigate whether
MPs induce apoptosis and autophagy on endothelial cells
and whether TNFα carried on their surface was respon-
sible for this effect. Our in vitro results on EA.hy926 cells
showed that at baseline (T0), serum RA-MPs significantly
increased both apoptosis and autophagy levels compared
to untreated cells, in a dose-dependent manner (p = 0.005
and p = 0.02, respectively) (Fig. 6a–d).
After 4 months of in vivo treatment with ETA,
RA-MPs did not significantly change these parameters
(p > 0.05 versus untreated cells for both parameters)
(Fig. 6e, f ). These effects were comparable to those
Fig. 3 Plasma levels of microparticles (MPs) in patients with rheumatoid arthritis (RA) at time zero (baseline (T0)) and after 4 months of treatment
(T4) and in healthy controls (HC) and surface expression of TNFα. a Relative distribution of total MPs (TMPs), platelet MPs (PMPs), leukocyte MPs
(LMPs) and endothelial MPs (EMPs) in 20 patients with rheumatoid arthritis (RA) and 20 healthy controls (HC). b, c Relative distribution of TMPs,
PMPs, LMPs, EMPs (a) and EMPs annexin-V (AV)+ (c) in patients with RA at time zero (baseline (T0) and 4 months after treatment (T4). d Relative
distribution of the percentage of the expression of TNFα on the surface of MPs from patients with RA and HC. e Relative distribution of TNFα
expression on MPs from patients with RA at T0 and T4. Each data point represents a single subject; horizontal lines show the median. Groups
were compared using Student’s t test; *p < 0.05
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obtained with the same number of MPs from HC
(Fig. 6e, f ). Interestingly, in the same experiment de-
scribed above, treatment with the 3MA restored a situ-
ation comparable to that at T0, with an increase in
endothelial apoptosis after autophagy block in EA.hy926
cells treated with MPs at T4, asserting the protective
role of autophagy (Fig. 6e, f ). The experiments reported
above showed the results at 16 h, but a cellular response,
comparable to that obtained at 16 h, had begun by 6 h
when the cells were incubated with RA-MPs, (data not
shown). However, at 24 h, 48 h, and 72 h the cellular re-
sponse in terms of apoptosis and autophagy gave rise to
confused and uninterpretable results, probably because,
after some hours, other surface molecules started a cel-
lular response, or the MPs fused themselves with the
cells or were internalized, and so the molecular content
of MPs may have altered the initial response (data not
shown).
Moreover, in vitro studies showed that RA-MPs
treated with ETA were no longer able to significantly
modulate apoptosis and autophagy in EA.hy926 cells. In
particular, when MPs were treated with ETA at 10 μg/
ml, both endothelial apoptosis and autophagy reached
levels comparable to those of untreated cells (p = 0.01
and p = 0.02, respectively versus cells treated with
RA-MPs at T0), to confirm possible involvement of
TNFα carried on MPs in the induction of apoptosis and
autophagy (Fig. 6g, h).
Finally, the result of western blot for NF-kB showed a
significant decrease in p65 protein when endothelial
cells were incubated with RA-MPs purified at T0 and
treated with ETA at 10 μg/ml (p = 0.02 versus cells
treated with RA-MPs at T0). This result confirms the
hypothesis that MPs carry TNFα on their surface, which
activates TNF-signaling pathways by interaction with its
surface receptors (Fig. 7).
Discussion
In our study, for the first time we demonstrated TNFα
expression on the surface of MPs from patients with
RA [22]. Higher circulating levels of TNFα are present
in serum from patients with RA, and TNFα itself is able
to directly damage endothelial function triggering NF-κB
activation and accumulation of reactive oxygen species
(ROS) [23].
Some evidence indicates a beneficial effect of TNF in-
hibitors on vascular wall physiology, increasing the pos-
sibility that TNF blockade may improve endothelial
function, with consequent improvement of arterial stiff-
ness and reduced progression of subclinical atheroscler-
osis [24, 25]. However, clinical studies conducted to
investigate the effect of anti-TNF therapy on endothelial
function in patients with RA have had contradictory re-
sults, generating controversy on this subject.
Based on our results and these considerations, we hy-
pothesized that TNFα carried on the surface of RA-MPs
could participate in the atherosclerotic process in pa-
tients with RA. Impaired endothelial cell function is a
hallmark of atherosclerosis. The endothelial dysfunction
is directly associated with the development of athero-
sclerosis, and it is present during all stages of the dis-
ease. Moreover, alterations in endothelial function
precede morphological atherosclerotic changes [26]. In-
jury to the endothelium is believed to be a preliminary
event in most vascular diseases [27]. Furthermore, those
alterations could include an imbalance between apop-
tosis and autophagy pathways.
Endothelial apoptosis has been associated with multiple
cardiovascular events that cause vascular wall damage and
atherosclerotic plaque, and consequently it promotes vas-
cular injury [28]. MPs have been shown to initiate cell
death when applied to cultured primary rat brain micro-
vascular endothelial cells (RBMVECs) and a variety of dif-
ferent mechanisms have been identified [29].
Previous studies showed that MPs derived from hu-
man umbilical vein endothelial cells [30] and platelets
[31] contain caspase 3, and Schneider et al. [32] have
suggested that circulating MPs induce apoptosis by the
transfer of caspases into target cells. In relation to this,
Abid Hussein et al. [30] suggest that MPs could be
phagocytosed by cells, causing the release of caspase 3
within the cell itself and initiating apoptosis. In this
study, treatment of MPs with a caspase 3 inhibitor sig-
nificantly improved cell survival, indicating that the MPs
impart pro-apoptotic caspase 3 signals.
Fig. 4 Surface expression of TNFα after incubation of rheumatoid
arthritis (RA)-microparticles (MPs) with etanercept (ETA). Percentage of
surface (s)TNFa expression on RA-MPs is shown after in vitro incubation
with ETA at different concentrations for 2 h. Values are expressed as
means ± SD; *p < 0.05
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Moreover, many studies showed that basal levels of au-
tophagy are protective for the endothelium, continuously
stimulated by mechanical and physical stress [33]. During
injury, endothelial cell autophagy may occur to protect
the cells from damage, while the failure of autophagy re-
sults in endothelial cell apoptosis, leading to the break-
down of the integrity of endothelium to induce the local
lipid deposition into atheroma, plaque instability, and even
acute coronary occlusion and death [34–37]. Nevertheless,
the mechanisms that control the autophagy of endothelial
cells are still limited. Moreover, autophagy has been
shown to play an important role in endothelial cells to
prevent development of atherosclerosis.
From the discovery of MPs up to now there has been no
scientific evidence of the involvement of MPs in the regula-
tion of autophagy pathway. Thus, in light of the numerous
reported data, we can assume that MPs could be involved
in alteration of apoptosis and autophagy, which together
could contribute to the formation and progression of ath-
erosclerotic plaque [38]. On the basis of this observation,
after investigating surface expression of TNFα on MPs
purified from patients with RA, we evaluated if MPs were
able to modulate endothelial apoptosis and autophagy in
vitro, and if TNFα carried on the surface of MPs could be
involved in these cellular processes. In this regard Schock
and coworkers identified three independent pro-apoptotic
Fig. 5 Correlation between the percentage of surface (s)TNFα expression on rheumatoid arthritis (RA)-microparticles (MPs) and clinical parameters
of patients with RA. Correlation and linear regression analysis of sTNFα expression on MPs from patients with RA and Disease Activity Score in 28
joints (DAS 28), tender joints (TJ), swollen joints (SW), Clinical Disease Activity Index (CDAI) and Health Assessment Questionnaire (HAQ) (r and p
values are shown on each diagram)
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signals induced by MPs on RBMVECs cells: caspase 3 and
activation of TNF-related apoptosis-inducing ligand
(TRAIL) and TNF receptors. To support our last point on
the induction of apoptosis by sTNF-MPs on EC, this study
showed that treatment with a neutralizing antibody to
TRAIL and TNF receptor blocker did improve cell survival.
Genetic analysis confirmed that Tumor necrosis factor re-
ceptor 1 and 2 (TNFR1, TNFR2) and TRAIL receptor 4 are
present in the cells. TRAIL may activate the extrinsic apop-
totic pathway, but in some circumstances may activate
Fig. 6 Induction of apoptosis and autophagy in EA.hy926 cells by microparticles (MPs) isolated from patients with rheumatoid arthritis (RA) after in
vivo and in vitro treatment with etanercept (ETA) and by MPs isolated from healthy controls (HC). a Flow cytometry analysis of apoptosis in untreated
MPs and MPs treated with EA.hy926 cells. Results obtained in a representative experiment are shown. Numbers in the upper and bottom right
quadrants of each plot refer to annexin-V (AV)/propidium iodide (PI) double-positive cells and to AV single-positive cells, respectively. b Mean ± SD of
the percentages of AV-positive cells obtained in three independent experiments; *p < 0.05. c, d Western blot analysis of LC3-II (left panel) and p62
(right panel) levels in EA.hy926 cells cultured with MPs purified from patients with RA at time zero (baseline (T0)), in the absence (c) or in the presence
(d) of lysosomal inhibitors E64d and pepstatin A (PepA). Blot shown is representative of three independent experiments. e, f Flow cytometry analysis
of apoptosis (e) and western blot analysis (f) of LC3-II in EA.hy926 cells cultured with (i) MPs purified from patients with RA after 4 months of treatment
with ETA, (ii) MPs purified from HC, and (iii) in the presence or absence of the autophagy inhibitor 3MA. g, h Flow cytometry analysis of apoptosis (g)
and western blot analysis (h) of LC3-II (left panel) and p62 (right panel) levels in EA.hy926 cells cultured with MPs purified from patients with RA at T0
and with MPs from patients with RA at T0 in vitro-treated with ETA. e-h Mean ± SD of the percentages of AV-positive cells obtained in three
independent experiments is reported and densitometry analysis of LC3-II and p62 levels relative to β-actin is shown. Values are expressed as means ±
SD; *p < 0.05. FSC, forward scatter; SSC, side scatter
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pro-survival or proliferative pathways [29]. TNF is synthe-
sized as a type-2 transmembrane protein and cleaved by
the tumor necrosis factor-alpha-converting enzyme (TACE)
ADAM17 to release soluble TNF, which may then activate
TNF receptors. The authors showed that treating MPs with
the TACE inhibitor (TAPI-0) prior to applying MPs to cul-
tured cells provides a significant improvement in cell sur-
vival. This result indicates that TACE is present and active
in MP membranes. Given the small size of MPs it is uncer-
tain whether they are able to shed soluble TNF for an ex-
tended period of time.
According to these reported data, our results confirm
that MPs from RA at T0 significantly increased apop-
tosis in endothelial cells. Interestingly, MPs purified
from RA at T4, after in vivo treatment with ETA, and
RA-MPs after in vitro treatment with ETA, were no lon-
ger able to significantly modify this parameter.
We obtained the same results for autophagy; indeed
MPs obtained from RA at T0 significantly increased
autophagy in endothelial cells and MPs purified from
RA after in vivo treatment with ETA, and RA-MPs after
in vitro treatment with ETA, were no longer able to sig-
nificantly modify the autophagy pathway. The experi-
ments with the 3MA, which is able to block autophagy
and increase apoptosis of endothelial cells treated with
RA-MPs, led us to suppose that MPs, if they induce cell
death on one side, on the other side they induce cells to
upregulate autophagy as a protective mechanism, at least
at an early stage.
Furthermore, we demonstrated that RA-MPs induced
an increase in NF-kB expression in endothelial cells, and
that RA-MPs in vitro treated with ETA did not. These
conclusive results support the concept, already proposed
in other studies [39, 40], that the TNF transported on the
surface of MPs interacts with TNF receptors on endothe-
lial cells and activates the TNF-signaling cascade, includ-
ing apoptosis and autophagy pathways.
Moreover, we observed significant correlation between
DAS28 and TNFα expression on the surface of RA-MPs.
This result supports other clinical observations that
demonstrated the efficacy and safety of ETA in patients
with active RA.
Finally, the interpretation of the ELISA results, i.e. that
serum TNF does not change or increase after therapy, as
demonstrated in other studies [41, 42], induced us to
hypothesize the possibility of using surface expression of
TNF on MPs as a possible therapy response marker. Ob-
viously, to confirm this statement we need a far greater
cohort of patients.
Conclusions
Our results suggest that MPs isolated from patients with
RA could exert their pathological effect on endothelial
cells by TNFα expressed on their surface. In vivo treat-
ment with ETA attenuates this effect, probably binding
and blocking the TNF carried on the surface of MPs, as
confirmed by our in vitro studies. To conclude, these re-
sults show a new pathway of endothelial damage mediated
by MPs and confirm the protective effect of anti-TNF
therapy against endothelial damage in patients with RA.
Certainly, we cannot assume that sTNF on MPs is the
only architect of a cellular response; we hypothesize that it
acts in synergy with multiple factors, some of which are
already widely discussed in the literature, like serum TNF.
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